FindTrial
Sign In

20 µg recombinant hepatitis B vaccine at months 0, 1, and 6

BIOLOGICAL3 trials

Sponsors

Shanxi Medical University

Conditions

Hepatitis B Vaccine

Phase 4

Immunogenicity and Persistence of Hepatitis B Vaccination in HIV-Infected Patients
NCT03962803
Shanxi Medical UniversityHepatitis B Vaccine
Start: 2019-06-05End: 2023-12-31Target: 300Updated: 2019-05-24
Research on Optimal Immunization Strategy of Hepatitis B Vaccine in Chronic Kidney Disease Population
NCT03962881
Shanxi Medical UniversityHepatitis B Vaccine
Start: 2019-05-25End: 2023-12-31Target: 300Updated: 2019-05-24
Immunogenicity and Persistence of Hepatitis B Vaccination in Methadone Maintenance Treatment Patients
NCT03962816
Shanxi Medical UniversityHepatitis B Vaccine
Start: 2019-05-26End: 2023-12-31Target: 300Updated: 2019-05-24

Related Papers

Immunogenicity persistence after four intramuscular triple-dose or standard-dose hepatitis B vaccine in patients receiving methadone maintenance treatment: A 1-year follow-up study in China
Human Vaccines & Immunotherapeutics2025-01-17
Immunogenicity, Safety, and Persistence Induced by Triple- and Standard-Strength 4-Dose Hepatitis B Vaccination Regimens in Patients Receiving Hemodialysis
The Journal of Infectious Diseases2024-10-08
Duration of immunogenicity of high-dose and prolonged-schedule hepatitis B vaccine among patients with chronic kidney disease: A one year follow-up study in China
Expert Review of Vaccines2022-08-132 citations
Immunogenicity and safety of 4 intramuscular standard-dose and high-dose hepatitis B vaccine in people living with HIV: a randomized, parallel-controlled trial
Expert Review of Vaccines2022-03-214 citations
Immunogenicity, safety, and compliance of high- and standard-strength four-dose hepatitis B vaccination regimens in patients receiving methadone maintenance therapy in China: a randomized, parallel-arm controlled trial
Expert Review of Vaccines2021-09-103 citations
Immunogenicity and safety of a high-dose and prolonged-schedule hepatitis B vaccine among chronic kidney disease patients: a randomized, parallel-controlled trial
Expert Review of Vaccines2021-05-315 citations